

Date: 15/11/2019.

To,
The Manager
Listing Compliance Department,
BSE Limited (Bombay Stock Exchange Limited),
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001.

Dear Sir/Madam,

Ref: In continuation to the Outcome of Board Meeting submitted on 14th November, 2019 (Script Id "BAJAJHCARE", Script Code "539872").

Sub: Outcome of Board Meeting held on 14th November, 2019 & Submission of financial result.

In continuation to our letter dated 14th November, 2019, we have submitted outcome of Board Meeting held on 14th November, 2019, we inadvertently fail to attach Limited Review Report along with Unaudited Financial result.

We hereby submitting full set of unaudited financial result along with Limited Review Report.

Inconvenience caused is highly regretted.

Thanking you,

Yours faithfully,

For and on behalf of Board of Directors of Bajaj Healthcare Limited

Mr. Aakashkumar Keshari Company Secretary



Date: 14/11/2019.

To,
The Manager
Listing Compliance Department,
BSE Limited (Bombay Stock Exchange Limited),
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001.

Dear Sir/Madam,

Ref: Script Id "BAJAJHCARE", Script Code "539872".

Sub: Outcome of Board Meeting held on 14th November, 2019 & Submission of financial result.

We hereby inform you that at the meeting of the Board of Directors of our Company held today i.e. 14th November, 2019 has considered and approved the following:

Unaudited Standalone Financial result for the Quarter/Half year ended on 30th September, 2019 along Limited Review Report.

We wish to inform you that Board Meeting commenced today at 04.00 p.m. and concluded at 06.15 p.m.

We are enclosing herewith the copy of approved financial result.

You are requested to kindly take the same on record.

Thanking you,

Yours faithfully,

For and on behalf of Board of Directors of Bajaj Healthcare Limited

Mr. Aakashkumar Keshari Company Secretary



Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to The Board of Directors of Bajaj Healthcare Limited

- 1. We have reviewed the accompanying statement of unaudited standalone financial results of Bajaj Healthcare Limited (the "Company") for the quarter ended September 30, 2019 and year to date from April 1, 2019 to September 30, 2019 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations"). Attention is drawn to the fact that the Statement of cash flows for the corresponding period from April 1, 2018 to September 30, 2018, as reported in these unaudited standalone financial results have been approved by the Board of Directors of the Company but have not been subjected to review.
- 2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in applicable Accounting Standards "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standards specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Paresh Rakesh & Associates

Chartered Accountants

FRN: 119728W

Rakesh Chaturvedi M. no: 102075

UDIN: 19102075AAAAGF5744

Date: 14th November 2019

Place: Thane

BAJAJ HEALTHCARE LIMITED

(CIN No.: L99999MH1993PLC072892)

STATEMENT OF ASSETS & LIABILITIES AS AT 30th SEPTEMBER 2019

(Rs in Lakhs)

		(Rs in Lakn
Particulars	As at	As at
	30.09.2019	31,03,2019
	(Unaudited)	(Audited)
A EQUITY AND LIABILITIES		
A BQUITTAND DIADILITIES		
1 Shareholders' funds	4 270 00	689.
a) Share Capital	1,379.92	
b) Reserves and Surplus	12,182.64	12,220
Sub - Total - Shareholders' Funds	13,562.56	12,910
2 Non-current liabilities	0.014.00	1 770
a) Long - term borrowings	2,014.72	1,739
b) Deferred Tax Liabilities (net)	157.37	158
c) Long - term provisions	146.67	142
Sub - Total - Non-current Liabilities	2,318.76	2,040
3 Current liabilities	E 40E 40	E 400
a) Short - term borrowings	5,485.48	5,488
b) Trade payables		
(i) Total outstanding dues of micro enterprises and small enterprises	2 400 95	2.000
(ii) Total outstanding dues of creditors other than micro enterprise & small enterprises	3,699.85	2,998
c) Other current liabilities	2,714.38	2,561
d) Short-term provisions	256.93	11 723
Sub - Total - Current Liabilities	12,156.64	11,733
TOTAL - EQUITY AND LIABILITIES	28,037.97	26,68
3 ASSETS		
1 Non-Current Assets		
a) Fixed Assets	13,405.36	12,96
b) Non-Current investments	500.31	
Sub - Total - Non-Current Assets	13,905.67	12,96
2 Current Assets		
a) Current investments	-	
b) Inventories	3,053.32	3,00
c) Trade receivables	8,468.92	7,81
d) Cash and cash equivalents	689.07	78
e) Other current assets	1,920.99	2,11.
Sub - Total - Current Assets	14,132.30	13,710
TOTAL ASSETS	28,037.97	26,689

Notes

The above results were reviewed by the Audit Committee and approved by the Board of Directors of the Company in at their respective meeting held on 14th November 2019.

2 The Figures of the Previous year have been Re-grouped, Re-arranged, Re-Classified wherever considered necessary.

By Order of the Board For Bajaj Healthcare Limited

Mr. Anil Jain D.No.: 00226137

Managing Director

Date: 14th November 2019

Place: Thane

BAJAJ HEALTHCARE LIMITED

(CIN No.: L99999MH1993PLC072892)

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER YEAR ENDED ON 30TH SEPTMBER, 2019

(Rs. In Lakhs Except for Earnings Per Share

Particulars	Quarte	r Ended	Six Months Ended			Year Ended
	30.09.2019	30,06.2019	30.09.2019	31.03,2019	30,09,2018	31.03.2019
	(UnAndited)	(UnAudited)	(UnAudited)	(Audited)	(Unaudited)	(Audited)
I. Revenue from operations	10,054.58	9,169.38	19,223.96	18,110.80	18,906.57	37,017.37
II. Other Income	11.68	41.17	31.91	28.63	68.54	97.17
III. Total Revenuc (I+II)	10,066.26	9,210.55	19,255.87	18,139,43	18,975.12	37,114.55
IV. Expenses (a) Cost of materials consumed (Including Other Direct Expenses)	8,382.96 -311.49	7,007.71 284.89	15,390.67 -26,60	13,438.70 707.63	15,694.60 -1,037.82	29,133.30 -330.20
(b) Changes in Inventories of Finished Good(c) Employee benefits expense(d) Finance Costs	773,57 157,43	635,00 182,67	1,408.57 340.10	1,316.88 407.36	1,145.01 394.42	2,461,90 801.78
(d) Prinance Costs (d) Depreciation and amortisation expense (e) Other expenses	295,23 309,54	294.15 344.25	589,38 632,86	580.61 297.22	560.40 1,192.56	1,141.00 1,489.79
Total Expenses	9,607.24	8,748.67	18,334.98	16,748.40	17,949.17	34,697.57
V. Profit before Exceptional and Extra Ordinary Items	459.01	461.88	920.89	1,391.03	1,025.94	2,416.98
VI. Exceptional items VII. Profit before Extra Ordinary Items	459,01	461.88	920.89	1,391.03 	1,025.94 -	2,416.98
VIII. Exceptional items IX. Profit Before Tax	459.01	461.88	920,89	1,391.03	1,025,94	2,416.9
X. Tax Expense (a) Current tax	110,00 0,76	140.00 -2.30	250.00 -1.54	345.00 35.13	330,00 3,79	675,0 38,9
(b) Deffered Tax (c) Earlier Years	20,52	137.70	20.52 268.97	5,16 385,30	66.86 400.65	72.00 785.9
Total Tax Expenses XI. Profit (Loss) from Continuing Operations	131,27 327,74	324.18	651,92	1,005.74	625,29	1,631.0
XII, Profit (Loss) from Discontinuing Operations XIII, Profit (Loss) for the period (IX + X)	327,74	324,18	651,92	1,005.74	625.29	1,631.03
XII., Proint (2008) for the period (X + X) XIV. Paid-up Equity Share Capital Face Value Rs. 10/-)	1,379.92	1,379.92	1,379.92	689.96	689.96	689.96
XV. Reserves excluding revaluation reserves as per Balance Sheet of Previous accounting Year	-	-	-	_	-	8198.2
XVI. EPS (Not Annualised) (a) Basic	2.38	2,35	4.72	3.64	2.27	11.8
(b) Diluted	2.38	2.35	4.72	3.64	2.27	11.8

^{1.} The above results were reviewed by the Audit Committee and approved by the Board of Directors of the Company in at their respective meeting held on 14th November 2019

^{2.} The Financial Account of the Company are prepared under Indian GAAP as the Company was listed in SME segment of BSE Ltd as on 31st March 2019 and migrated to Main Board on 29th May 2019. Ind-AS will be applicable from 1st April 2020.

^{3.} Comparative Figures for Quarters ended 30th September 2018 is not provided, since the company was listed in SME segment until 31st March 2019 and was required to prepare & publish half yearly results instead of quaterly results upto 31st March 2019. Such, half yearly figures published are provided which are not Comparable.

BAJAJ HEALTHCARE LTD. CASH FLOW STATEMENT FOR THE PERIOD 30th SEPTEMBER 2019

(CIN No.: L99999MH1993PLC072892)

		30th Sept. 2019 30th Sep			t 2018	
et - NT -	Particulars	Amt in Rs.	Total Control of the	Amt in Rs.		
Sr No	Tarronius -					
A CONTRACTOR						
A	CASH FLOW FROM OPERATING ACTIVITIES					
	Net Profit Before Tax		920.89		1,025.94	
	Adjustments for:					
	Depreciation	589.38	-	560.40		
	(Profit)/loss on sale of Assets	-		0.46		
	Interest & Finance Charges	340.10		394.42	·	
	Interest on FD	(7.30)		(7.16)		
	Provision for Employee Benefits & Leave Enchashment	19.64				
	Insurance Claim Receivable			(47.19)	200.00	
	Dividend Income	(0.04)	941.76	(0.04)	900.88	
İ				ļ	1 026 02	
	Operating Profit before Working Capital Changes		1,862.66		1,926.83	
	Adjustments for:	(100.40)		4.70		
	(increase)/Decrease in Other current assets	(109.49)	į.	4.78 (537.25)		
	(increase)Decrease In Sundry Debtors	(656.23)	1	, ,		
	(Increase)/Decrease In Inventories	(48.53)	-	(562.37)	•	
l .	(D)	050.01		(488.96)		
, ·	Increase /(Decrease) in non current and current liabilities	850.91	36.65	(400.90)	(1,583.80)	
			36.65 1,899.31		343.03	
	Cash generated from operations				(878.72)	
	Income Tax Paid		(393.69) 1,505.62		(535.69)	
	Net Cash flow from Operating activities		1,303.02		(555.09)	
В	CASH FLOW FROM INVESTING ACTIVITIES					
Б	Purchase of Fixed Assets	(400.60)		(551.99)		
	Increase/(Decrease) in Capital Wip	(626.64)		(82.16)		
	Salc Of Fixed Assets	` _ `		5.22		
	Interest on FD	7.30		7.16		
	Payment to Gratuity Fund	(15.00)		(14.50)		
	Dividend Income	0.04		0.04		
	Net Cash used in Investing activities		(1,034.89)		(636.23)	
	_					
С	CASH FLOW FROM FINANCING ACTIVITIES	Ì				
	Proceeds From Long Term Borrowing	296.43		(382.08)	1	
	Increase of Investment in Preference Shares	(500.00)				
	Repayment Of Unsecured Long Term Borrowing	(20.97)		(15.13)		
	Increase /(Decrease) Of Short Term Borrowing From Bank	130.69		1,458.95		
	Increase /(Decrease) Of Borrowing From Director & Inter			, <u>, , , , , , , , , , , , , , , , , , </u>		
	corpoates	(133.86)		(49.57)	***************************************	
	Interest paid	(340.10)		(394.42)		
	Dividend Paid	-		-		
	Dividend Distribution Tax Paid	-	, <u></u>	-		
	Net Cash used in financing activities		(567.81)		617.75	
	·				-	
	Not in proper in Coah & Coah Pouringlants (A+D+C)		(97.08)		(554.17)	
	Net increase in Cash & Cash Equivalents (A+B+C)		(37,08)	ŧ	(334.17)	
	Cook and Cook conjugate as at 01 04 0010		786.15		828.56	
	Cash and Cash equivalents as at 01.04.2019 Cash and Cash equivalents as at 30.09.2019		689.07	Ī	274.39	
	Cash and Cash equivalents as at 00.05.2015		005.07		1.55	

For and on behalf of the Board

For BAJAJ HEALTHCARE LIMITED

Mr. Anil Jain D.No.: 00226137

Managing Director

Place: Thane Date: 14/11/2019

BAJAJ HEALTHCARE LIMITED

(CIN No.: L999999MH1993PLC072892)

REPORT ON SEGMENT RESULTS FOR QUARTER ENDED ON 30TH SEPTEMBER, 2019

Annexure : A

(Rs. In Lakhs)

							(Rs. In Lakhs)
Sr No	Particulars	Quarter	Ended	S	Year Ended		
51 110		30.09.2019	30.06.2019	30.09.2019	31,03.2019	30.09.2018	31,03.2019
		(UnAudited)	(UnAudited)	(UnAudited)	(Audited)	(UnAudited)	(Audited)
A	Segment Revenue (Excluding Intersegment Revenue)						
	Bulk Drugs	9280,35	8674,87	17955.22	17631.27	18524,04	36155.3
	Formulations	774.22	494.51	1268,73	479.53	382.53	862,0
	Total	10,054.58	9,169.38	19,223.96	18,110.80	18,906.57	37,017.37
	Segment Revenue (Intersegment Revenue) Bulk Drugs	424.70	563,34	988.04	297.78	378.63	676.41
	Formulations	10.80	31.06	41.86	33.22	51.88	85.10
	Total	435.49	594.40	1,029.89	331.00	430.50	761.51
	Gross Segment Revenue (Including Intersegment				-		
	Revenue) Buik Drugs	9705.05	9,238.21	18943.26	17929,05	18902.67	36831.73
	Formulations	785.01	525,58	1310.59	512,76	434,41	947.1
	Total	10,490.06	9,763.79	20,253.85	18,441.80	19,337.08	37,778.88
1	II. Segment Results Profit / (Loss) Before Tax & Finance Cost Bulk Drugs Formulations	910.63 -5.59	- 1,088,10 -99,30	1,998.73 -104.88	2,222.18 -126,56	2,734.43 -121.50	4,956.61 -248.06
	Total	905,05	988.80	1,893.85	2,095.62	2,612.93	. 4,708.55
	Less : Interest Other Unallocable Expenditure (Net)	157.43 288.61	182.67 344.25	340.10 632.86	407.36 297.22	394,42 1,192.56	801.78 1,489.79
	Total Profit Before Tax	459.01	461.88	920.89	1,391.03	1,025,94	2,416.98
C	I. Segment Assets Bulk Drugs	25506.47	25,008.11	25,506.47	25,099.65	26,014.71	25,099.65
	Formulations	2031.19	1,967.82	2,031.19	1,584.80	1,608.04	1,584.80
	Others	500.31	500.31	500.31	0.31	0.31	0.3
	Total	28,037.97	27,476.24	28,037.97	26,684.76	27,623.05	26,684.70
	II. Segment Liabilities Bulk Drugs	13467.62	12,552.71	13,467.62	12,466.14	14,769.99	1
	Formulations	453,74	582,17	453,74	331,64	283.16	
	Others ·	554.04	1,106.53	554.04	976,33	664,91	976.3
	Total	14,475.40	14,241.41	14,475.40	13,774.11	15,718.06	
	Total Capital Employed	13,562.56	13,234.83	13,562.56	12,910.64	11,904.99	12,910.6
	Total (II+III)	28,037.97	27,476.24	28,037.97	26,684.76	27,623.05	26,684.70

For and on behalf of the Board For BAJAJ HEALTHCARE LIMITED

Anil pain Director D.No.: 00226137

Place : Thane

Date: 14th November 2019